US › Healthcare

Omeros Corporation (OMER)

US · Healthcare · Biotechnology

$12.94+3.03%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$9.9M
Revenue YoY
+2301.2%
Net profit
$56.1M
Profit YoY
+267.5%
EPS
$0.57
EPS estimate
$-0.39
Net margin
566.7%

EPS came in at 0.57 against a street estimate of -0.39 — a beat of 246.2%.

Key statistics

Market cap
$856.9M
P/E
10.4
Forward P/E
58.1
P/B
8.44
Book value
$-0.88
EPS (TTM)
$1.14
52-week high
$17.65
52-week low
$3.60
50-day MA
$10.34
200-day MA
$10.98
Beta
2.55

Analyst view

Analysts rate Omeros Corporation a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $33.00.

Shareholding

Insiders
3.56%
Institutions
44.72%

Largest institutional holders

FundStake
BlackRock Inc7.34%
Ingalls & Snyder LLC4.92%
Vanguard Capital Management, LLC4.12%
UBS Group AG3.23%
State Street Corp2.65%
Stifel Financial Corp2.53%
Geode Capital Management, LLC2.42%
CI Private Wealth LLC1.11%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Omeros Corporation — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.